NIGMS MIRA R35 Eligibility Guide 2026

Full answer: The first check is the notice: PAR-26-121 covers established and new investigators (plus renewals for current MIRA grantees), while early stage investigators apply through PAR-27-032, according to the NIGMS MIRA page (opens in a new tab).

Data note: This guide uses PAR-26-121 on Grants.gov (opens in a new tab), the NIGMS MIRA program page (opens in a new tab), the NIH R35 activity-code page (opens in a new tab), Grants.gov (opens in a new tab), the live NIGMS MIRA R35 program record, and Grantsights program records, rechecked on October 9, 2026.

Source review by Grantsights, June 3, 2026: We rechecked NIH PAR-26-121, NIGMS MIRA guidance, the NIH R35 activity-code page, Grants.gov package status, and NIGMS MIRA FAQs. Where official sources stop: PAR-26-121 is the active route for established and new investigators (applications accepted 2026 to 2028), and NIGMS says early stage investigators should apply through PAR-27-032 (applications accepted through February 6, 2029). Either way, the source pages keep the key distinction intact: MIRA funds an investigator's NIGMS research program, not a larger version of one R01. Based on our analysis, a bad fit is a PI using MIRA to bundle unrelated projects, pursue disease-specific work owned by another institute, or avoid writing a sharper R01. For example, a basic-science investigator with a coherent program across related mechanisms can fit MIRA, while a team centered on one clinical endpoint may need another NIH route.

Who this is for: This guide is for principal investigators, department administrators, sponsored-research offices, and research development teams checking NIGMS MIRA R35 eligibility before deciding whether to frame the work as an investigator program or as one or more R01 projects.

According to PAR-26-121 on Grants.gov (opens in a new tab), this MIRA route is a clinical-trial-optional R35 notice for investigators whose research program fits NIGMS mission. The NIGMS MIRA page (opens in a new tab) explains the broader program goal, and the live NIGMS MIRA R35 program record should be checked for status and award data. One correction to a common assumption: PAR-26-121 isn't the ESI route. Its Grants.gov synopsis says current early stage investigators should apply through the ESI MIRA notice instead.

The search-intent problem is not "What is MIRA?" It is "Should I move my NIGMS work into an investigator-program frame instead of an R01 frame?" Teams sometimes write MIRA like a large R01 with extra background. That is usually the wrong read. MIRA needs a research-program story, not just a project story.

Use this guide with the NIH R01, R21, R03, and K awards comparison, NIH grants complete guide, NIH R01 success-rate data, NIH Parent R21 clinical trial not allowed guide, NCMRR Early Career R03 guide, NIA Academic Leadership K07 guide, and the Grantsights grant database.

Last updated: October 2026

8 NIGMS MIRA R35 Eligibility Checks

Within 14 days, run this 8-step checklist before drafting.

According to NIH, R35 awards support a research program rather than one tightly bounded project. According to NIGMS, MIRA is meant to increase stability and flexibility for investigators working in NIGMS mission areas.

5 Source Facts Applicants Should Know

Within 7 days, put these 5 source facts into a route memo. First, according to NIH PAR-26-121, the current notice is clinical trial optional. Second, according to NIGMS, MIRA supports the investigator's research program in areas relevant to the institute. Third, according to NIH R35 activity-code guidance, R35 is not the same as R01. Fourth, according to Grants.gov, applicants still need to check the official application package and dates. Fifth, according to the NIGMS MIRA page, early stage investigators apply through a separate notice, PAR-27-032, not PAR-26-121.

What NIGMS Doesn't Tell You

The official MIRA pages explain the mechanism, but they don't score whether the research story is program-level enough. The practical gap is the gap between MIRA as a policy route and MIRA as a review narrative. A PI can be eligible and still write a weak application if the proposal reads like one R01 with a larger umbrella.

Grantsights analysis of award data and route evidence says applicants should apply when the PI can explain the unifying scientific direction, how current work fits together, and why MIRA beats separate R01s. If the proposal has one narrow hypothesis, one dataset, one device, or one disease endpoint outside NIGMS mission, it may be a bad fit.

For example, a university PI studying fundamental cell-signaling mechanisms across several related questions may fit if the work forms a coherent NIGMS program. A team building a disease-specific clinical trial endpoint may need another institute or R01 route. A PI with two unrelated projects shouldn't use MIRA to bundle them together. The route rewards coherence, not just size.

5 Bad-Fit Signals

Within 14 days, stop on these 5 signals. First, the work is not in NIGMS mission. Second, the application reads as one R01 project. Third, the PI cannot explain current support and overlap. Fourth, the project is mainly clinical, disease-specific, or applied in a way another NIH institute owns. Fifth, the team picked MIRA because it sounds larger, not because it fits the investigator program.

MIRA route errors often show up in the first 150 words. If the draft starts with one aim and one outcome, it may be an R01. If it starts with the PI's continuing research program, linked questions, and a reason MIRA will improve stability and direction, it is closer.

5 Route Choices Before Drafting

Within 7 days, compare 5 routes, plus one that isn't open yet. NIH posted a Grants.gov forecast for PAR-28-037 (opens in a new tab), an "Investigator-Focused Award (Parent R35)" for investigators at all career stages across institutes. It's a forecast, not an open notice, so check its status before planning around it.

Use the NIH R01, R21, R03, and K awards comparison if you're still deciding whether the problem is project funding, program funding, or career stage.

5 Fit Signals Readers Can Use

Within 14 days, use these 5 signals before drafting. Signal 1 is the program frame. Signal 2 is NIGMS mission fit. Signal 3 is current support mapping. Signal 4 is the R01 tradeoff. Signal 5 is budget and trial-role fit.

This page gives the decision path. If two or more signals are weak, R01 or another route is probably clearer. If they're strong, confirm the notice that matches the PI's career stage and start the program summary.

6 Reviewer-Risk Notes For MIRA Teams

Within 21 days, write 6 reviewer-risk notes before drafting the research strategy. Note 1 is the program frame. A common mistake is adding a broad title to an R01-style project. Reviewers need to see why the PI's continuing NIGMS research program is the unit of review. If the work has one aim, one endpoint, and one project endpoint, R01 may be cleaner.

Note 2 is mission fit. For example, a lab studying basic mechanisms of protein homeostasis across several linked systems may fit NIGMS MIRA. A lab running a disease-specific biomarker study may need another institute, even if the lab also studies basic biology. The bad fit is often visible before the budget: the disease endpoint owns the narrative and NIGMS mission becomes a footnote.

Note 3 is support overlap. The pitfall is listing current awards without explaining what MIRA replaces, absorbs, or changes. A 1-page support map helps, with columns for current project, institute, percent overlap, future plan, and MIRA effect. That map can prevent a confusing application.

Note 4 is the R01 tradeoff. According to NIGMS, MIRA is built around a research program. That means the applicant should be able to explain why separate R01s are worse. If the answer is only "fewer applications," the argument is thin. If the answer is that flexible support will let the PI follow linked NIGMS questions, the story is stronger.

Note 5 is the clinical-trial optional label. Optional status does not make MIRA a clinical-program route. If trial elements appear, write the NIGMS mission reason, the PI role, and why the work remains program-level basic research. Don't let trial language pull the proposal into another institute's lane.

Note 6 is the notice match. PAR-26-121 is for established and new investigators and MIRA renewals; early stage investigators apply through PAR-27-032. Confirm the PI's ESI status in eRA Commons before drafting, because an application under the wrong notice won't fit its eligibility rules.

5 Before-Drafting Questions

Within 10 minutes, answer these 5 questions before drafting. First, can the PI state the research program, not just a project? Second, can the team prove NIGMS mission ownership? Third, does the current support map make sense? Fourth, why is MIRA better than R01? Fifth, does any trial language create another-institute risk?

If the answers are weak, revise the route choice first. If MIRA may fit but the support map or mission claim is uncertain, contact the NIGMS program officers listed on the MIRA page before drafting. Program coherence, mission fit, support overlap, R01 tradeoff, budget logic, and trial boundary are the points to settle.

One extra check is worth doing before the PI commits to MIRA: write the title of 2 separate R01s the lab might otherwise submit. If those titles look unrelated, MIRA may look like a bundle. If they sit under one NIGMS research direction and the flexible program frame would make the science better, MIRA may be the cleaner route. That 10-minute exercise often exposes the real mechanism choice.

The reader should see NIGMS, MIRA, R35, PAR-26-121, clinical trial optional, R01 tradeoff, and program-frame risk in the first 150 words. If the page only defines the acronym, it cannot beat official sources or convert a serious PI.

5 FAQ Answers

Is PAR-26-121 clinical trial optional?

Yes. According to NIH PAR-26-121, the route is clinical trial optional, but optional status does not override NIGMS mission fit.

Is MIRA just a larger R01?

No. MIRA is an investigator-program route. If the work is one project, an R01 may be clearer.

Can disease-specific work fit MIRA?

Maybe, but only if the core science fits NIGMS mission. If another institute owns the disease mission, compare routes before drafting.

What should I check before drafting?

Check the notice that matches the PI's career stage (PAR-26-121 or PAR-27-032), the NIGMS MIRA page (opens in a new tab), and the live NIGMS MIRA R35 program record.

What should I prepare first?

Prepare a 1-page program summary, current support list, R01 comparison, budget sketch, trial-role note, and NIGMS mission paragraph.

Sources

• PAR-26-121 on Grants.gov (opens in a new tab)
• PAR-28-037 forecast on Grants.gov (opens in a new tab)
• NIGMS MIRA program page (opens in a new tab)
• NIH R35 activity code (opens in a new tab)
• Grants.gov (opens in a new tab)
• NIGMS MIRA R35 program record